GlassScriptPhysician profile
Mohamad Ayasso
NPI 1295726693
$47,984.72
in general payments reported to CMS, 2019-2025
15 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,178 · 2020: $6,851 · 2021: $5,540 · 2022: $11K · 2023: $8,973 · 2024: $10K · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,831 · Travel and Lodging: $1,024 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,325.00 |
| Food and Beverage | $2,831.17 |
| Travel and Lodging | $1,024.13 |
| Education | $148.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,432.41 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,470.75 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $551.01 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.93 | 2019-2021 | |
| Celgene Corporation | $70.06 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $63.47 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $57.86 | 2019-2020 | |
| Allergan, INC. | $35.58 | 2019-2020 | |
| Braintree Laboratories, INC. | $33.75 | 2019-2021 | |
| Gilead Sciences, INC. | $32.45 | 2019-2021 | |
| Genzyme Corporation | $29.41 | 2022 | |
| Ironwood Pharmaceuticals, INC | $28.43 | 2020 | |
| Ferring Pharmaceuticals INC. | $18.57 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.07 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.97 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Ayasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.